Skip to main content
Premium Trial:

Request an Annual Quote

ID Genomics Wins $3M NIH Grant to Develop UTI Diagnostic

NEW YORK (GenomeWeb) – ID Genomics announced that it has received a three-year, $3 million grant from the National Institutes of Health to continue development of a rapid genetic test for the diagnosis of urinary tract infections (UTIs) and prediction of antibiotic resistance. 

The test, called CloNeT, involves barcoding infecting bacteria in urine by detecting the presence or absence of a small number of single nucleotide polymorphisms via PCR. These barcodes are associated with various bacterial strains and linked to antibiotic resistance profiles. 

Analysis can be completed within 45 minutes, according to ID Genomics, and provides a physician with information on which antibiotic is best suited for a patient's particular infection.

With the NIH grant, ID Genomics aims to refine and validate CloNeT for the diagnosis of UTIs caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter spp, and Proteus mirabilis using clinical isolates from different geographic regions across the US.

It previously received a $3 million grant from the NIH to build a prototype of the test.

The company said it envisions the technology eventually being applied to other infectious diseases including sepsis and pneumonia, and that it aims to identify and monitor most antibiotic-resistant pathogens in a global epidemiological surveillance network.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.